Assessment of Subcutaneous vs Intravenous Administration of Anti–PD-1 Antibody PF-06801591 in Patients With Advanced Solid Tumors

Authors:

Abstract
Novel antitumor therapies that target the PD-1 (programmed cell death 1) receptor and its ligands (PD-L1 and PD-L2) can reverse cancer-mediated immune evasion.1 The PD-1 receptor is upregulated on activated effector T lymphocytes. Expression of PD-L1 is triggered on tumor cells and other immune cells upon cytokine release by activated T cells, and PD-L2 is mainly expressed on macrophages and dendritic cells.2-4 Binding of the PD-1 receptor to its ligands negatively regulates the antitumor immune response by inhibiting T-cell proliferation, cytokine production, and cytotoxic functions.5,6

This publication has 40 references indexed in Scilit: